Cancer patients receiving drugs to lower the risk of anaemia...
Published Tuesday 01 December 2009
Chemotherapy can result in insomnia
Insomnia occurs in approximately three-quarters of cancer patients who have...
Published Tuesday 01 December 2009
Osteoarthritis risk increased by high exercise levels
Men and women in middle age who exercise on a...
Published Monday 30 November 2009
Cancer genome changes increase cervical cancer relapse risk
Patients with cervical cancer are three to four times more...
Published Sunday 29 November 2009
More Medical News
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
Vasopressin analogues.
Desmopressin acetate - endocrine
DDAVP/Desmopressin Intranasal Solution: intranasal solution. DDAVP Tablets: white scored tablets marked with strength. DDAVP/Desmopressin Injection: ampoules.
DDAVP/Desmopressin Intranasal Solution: Desmopressin acetate 100 micrograms/mL. DDAVP Tablets: Desmopressin acetate 0.1 mg , 0.2 mg . DDAVP/Desmopressin Injection: Desmopressin acetate 4 micrograms/mL.
DDAVP/Desmopressin Intranasal Solution: Diagnosis and treatment of vasopressin-sensitive cranial diabetes insipidus; establishing renal concentration capacity. DDAVP Tablets: Treatment of vasopressin-sensitive cranial diabetes insipidus; treatment of post-hypophysectomy polyuria/ polydipsia. DDAVP/Desmopressin Injection: Cranial diabetes insipidus.
DDAVP/Desmopressin Intranasal Solution: Diabetes insipidus treatment, 0.1 - 0.2 mL once or twice daily. Diabetes insipidus diagnosis, 0.2 mL as single dose. Limit fluid intake to maximum 0.5 litres from 1 hour before to 8 hours after administration.
Renal function testing, 0.4 mL. DDAVP Tablets: Diabetes insipidus, initially 0.1 mg three times daily. Maintenance 0.1 - 0.2 mg three times daily. Post-hypophysectomy polyuria/ polydipsia, titrate dose according to urine osmolality.
DDAVP/Desmopressin Injection: 1 - 4 micrograms intramuscularly, subcutaneously or intravenously
DDAVP/Desmopressin Intranasal Solution: Diabetes insipidus treatment, 0.05 - 0.2 mL daily, infants may require a lower dose. Diabetes insipidus diagnosis, 0.2 mL as single dose. Limit fluid intake to maximum 0.5 litres from 1 hour before to 8 hours after administration. Renal function testing, up to 1 year, 0.1 mL; 1 - 15 years, 0.2 mL. DDAVP Tablets: Diabetes insipidus, initially 0.1 mg three times daily. Maintenance 0.1 - 0.2 mg three times daily. Post-hypophysectomy polyuria/ polydipsia, titrate dose according to urine osmolality. DDAVP/Desmopressin Injection: Doses from 0.4 micrograms (0.1mL) may be used.
Cardiac insufficiency, hypertension.
Exclude psychogenic polydipsia and alcohol abuse before initiating therapy. Renal impairment, cardiovascular disease, electrolyte imbalance, cystic fibrosis. Pregnancy. Avoid fluid overload.
Indometacin (indomethacin), tricyclic antidepressants, chlorpromazine, carbamazepine.
Headache, stomach pain, nausea. Hyponatraemic convulsions.
Ferring
(POM)
Published Friday 20 February 2009
Published Friday 20 February 2009
Published Thursday 19 February 2009
Published Wednesday 18 February 2009
Published Wednesday 18 February 2009
Published Tuesday 17 February 2009
Published Tuesday 17 February 2009
Published Friday 13 February 2009
Published Thursday 12 February 2009
Published Wednesday 11 February 2009
Published Tuesday 10 February 2009
Published Tuesday 10 February 2009
Published Monday 09 February 2009
Published Friday 06 February 2009
Published Friday 06 February 2009
Published Thursday 05 February 2009

Medical News